Formation Bio, Sanofi, and OpenAI Launch Muse to Accelerate Patient Recruitment

Formation Bio, OpenAI, and Sanofi have introduced Muse, an advanced AI tool designed to streamline patient recruitment in clinical trials, a process that is often slow, costly, and a barrier to faster drug development. Muse, the first AI tool of its kind in pharma, speeds up recruitment strategies and content creation, reducing timelines from months to minutes. By analyzing vast scientific literature, real-world evidence, and patient data, Muse identifies ideal patient profiles and generates recruitment materials tailored for diverse patient groups.

Developed with OpenAI’s models, Muse serves across therapeutic areas, with Sanofi set to implement it in upcoming Phase 3 trials for multiple sclerosis (MS). This collaboration aims to use AI-driven strategies to scale efficiency, inclusiveness, and compliance in clinical trials. Muse prioritizes patient diversity, automates compliance with regulatory standards, and integrates AI safety and data privacy, helping accelerate new treatments to market.

Emmanuel Frenehard, Chief Digital Officer at Sanofi, emphasizes Muse as a milestone in Sanofi's AI-driven transformation, enabling the company to bring breakthrough treatments to patients faster. Formation Bio’s CEO, Ben Liu, notes that Muse is just the start of many AI innovations they are developing to enhance drug development worldwide.

Click here to read the original news story.